{"id":33284,"date":"2023-03-01T14:10:54","date_gmt":"2023-03-01T13:10:54","guid":{"rendered":"https:\/\/www.abcsg.org\/?page_id=33284"},"modified":"2026-02-05T09:54:50","modified_gmt":"2026-02-05T08:54:50","slug":"abcsg-56-sascia","status":"publish","type":"page","link":"https:\/\/www.abcsg.org\/en\/abcsg-studien\/studies-in-treatment-phase-follow-up\/abcsg-56-sascia\/","title":{"rendered":"ABCSG 56 \/ SASCIA"},"content":{"rendered":"<table>\n<tbody>\n<tr>\n<td>Study Start:<\/td>\n<td>AT: FPI <strong>09\/2022 | <\/strong>Global: FPI <strong>12\/2020<\/strong> (GER)<\/td>\n<\/tr>\n<tr>\n<td>Coordinating Investigator:<\/td>\n<td>AT: <strong>Balic, Marija <br \/>\n<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Sample Size:<\/td>\n<td>AT: <strong>50 | <\/strong>Global: <strong>1332<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Description and status:<\/h3>\n<p>The ABCSG 56 \/ SASCIA is a GBG-sponsored, randomized, open-label, postneoadjuvant Phase III study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate, in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment. The primary objective of the study is to compare invasive disease-free survival (iDFS) and overall survival (OS) between patients treated with sacituzumab govitecan and patients who received treatment of physician&#8217;s choice.<\/p>\n<p>In addition, various biomarker analyses will be performed to investigate translational endpoints.<\/p>\n<p>The Recruitment was ended globally on 23 January 2024 with an over-recruitment of 1.391 patients. In Austria, a total of 34 patients were included at 13 trial sites.<\/p>\n<p>The regular end of study is set for the beginning of 2027. Subsequently, the ETERNITY project is planned, a registry for the long-term follow-up of safety and efficacy parameters of former SASCIA patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Study Start: AT: FPI 09\/2022 | Global: FPI 12\/2020 (GER) Coordinating Investigator: AT: Balic, Marija Sample Size: AT: 50 | Global: 1332 Description and status: The ABCSG 56 \/ SASCIA is a GBG-sponsored, randomized, open-label, postneoadjuvant Phase III study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate, in primary HER2-negative breast cancer patients with high relapse [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":32914,"menu_order":102,"comment_status":"closed","ping_status":"closed","template":"page-onepagestudy.php","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-33284","page","type-page","status-publish","hentry"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-08 01:09:17","action":"delete","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/33284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/comments?post=33284"}],"version-history":[{"count":5,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/33284\/revisions"}],"predecessor-version":[{"id":40950,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/33284\/revisions\/40950"}],"up":[{"embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/pages\/32914"}],"wp:attachment":[{"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/media?parent=33284"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abcsg.org\/en\/wp-json\/wp\/v2\/tags?post=33284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}